Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Extracellular Vesicles in Multiple Sclerosis: What are They Telling Us?
Erratum to: Altered serotonin transporter availability in patients with multiple sclerosis.
The role of complement in inflammatory diseases from behind the scenes into the spotlight.
Non-local spatial regularization of MRI T2 relaxation images for myelin water quantification.
Thalamic atrophy and cognitive impairment in clinically isolated syndrome and multiple sclerosis.
FTY720 induces apoptosis of m2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels.
Sox5 and c-Maf cooperatively induce Th17 cell differentiation via RORγt induction as downstream targets of Stat3.
Advanced techniques using contrast media in neuroimaging.
Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain.
Efficacy of A Telephone-Delivered Self-Management Intervention For Persons With Multiple Sclerosis: a Randomized Controlled Trial With a One-Year Follow-Up.
Effects of Reducing Suppressors of Cytokine Signaling-3 (SOCS3) Expression on Dendritic Outgrowth and Demyelination after Spinal Cord Injury.
Axonal motor protein KIF5A and associated cargo deficits in multiple sclerosis lesional and normal-appearing white matter.
[Cognitive Impairment in Multiple Sclerosis].
New insights into an autoimmune mechanism, pharmacological treatment and relationship between multiple sclerosis and inflammatory bowel disease.
Association of Cerebrospinal Fluid Levels of Lateral Olfactory Tract Usher Substance (LOTUS) With Disease Activity in Multiple Sclerosis.
Galanin is an autocrine myelin and oligodendrocyte trophic signal induced by leukemia inhibitory factor.
An integrated metabolomics approach for the research of new cerebrospinal fluid biomarkers of multiple sclerosis.
Control of IL-17 receptor signaling and tissue inflammation by the p38α-MKP-1 signaling axis in a mouse model of multiple sclerosis.
MS in South Asians in England: early disease onset and novel pattern of myelin autoimmunity.
Development of Activity-Related Muscle Fatigue during Robot-Mediated Upper Limb Rehabilitation Training in Persons with Multiple Sclerosis: A Pilot Trial.
Seroprevalence of NMO-IgG Antibody in Neuromyelitis optica (NMO) and Its Specificity in Differentiating NMO from Other Demyelinating Diseases with Overlap Symptoms: An Iranian Experience.
ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis.
Effect of in-painting on cortical thickness measurements in multiple sclerosis: A large cohort study.
Differential IL-10 production by DCs determines the distinct adjuvant effects of LPS and PTX in EAE induction.
Spinal Cord Normalization in Multiple Sclerosis.
Pages
« first
‹ previous
…
397
398
399
400
401
402
403
404
405
…
next ›
last »